Dave: the cost to enroll patients is quite expensi
Post# of 30027
Posted On: 10/01/2015 11:09:31 PM
Dave: the cost to enroll patients is quite expensive. Also, I think the ESS risk/reward ratio and near term revenue potential outweighs the risk that the Elto trial could turn out to be a dud.
Just watch the stock price to see what the market thinks...over 300k volume today with a intra day high over $2. The market is already speaking and it definitely likes what decisions were made.
It will take a few more days before we clear the overhead...should see $2 ++ shortly once again.
Just watch the stock price to see what the market thinks...over 300k volume today with a intra day high over $2. The market is already speaking and it definitely likes what decisions were made.
It will take a few more days before we clear the overhead...should see $2 ++ shortly once again.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼